NCT01223898CompletedPhase 1
An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 19
- Locations
- 1
- Primary Endpoint
- evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam in CML patients.
Study Overview
Brief Summary
This study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam (as a sensitive CYP3A probe) in CML patients. The following extension study does evaluate the safety of nilotinib.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with a cytopathologically confirmed diagnosis of Ph+ CML or Philadelphia chromosome- negative (Ph-) CML patients in accelerated or chronic phase who are resistant and/or intolerant against at least one prior therapy with a BCR-ABL tyrosine kinase inhibitor
- •Female or male ≥ 18 years of age
- •Patients who are nilotinib naïve at study entry, e.g. did not receive any nilotinib treatment prior to study
- •WHO Performance Status of ≤ 2
Exclusion Criteria
- •Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
- •Impaired cardiac function
- •History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis.
- •Patients actively receiving therapy with the prohibited co-medications (CYP3A4 inhibitors or inducers, or CYP2C inducers)
- •Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval
- •Treatment with immunotherapy or chemotherapy within 3 days (6 weeks for nitrosurea or mitomycin-C) prior to Day 1 or who have not recovered from side effects of such therapy.
- •Treatment with imatinib within 1 week prior to Day 1 or who have not recovered from side effects of such therapy.
- •Patients who have hypersensitivity to midazolam or related compounds
- •Other protocol-defined inclusion/exclusion criteria may apply
Arms & Interventions
Nilotinib
Experimental
Intervention: Tasigna (Drug)
Outcomes
Primary Outcomes
evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam in CML patients.
Time Frame: 2 weeks
Secondary Outcomes
- evaluate the safety and tolerability of multiple doses of nilotinib when midazolam is co-administered orally in CML patients.(2 weeks)
- Monitoring of safety of nilotinib during the extension study phase.(12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Myelogenous Leukemia, ChronicNCT00471497Novartis Pharmaceuticals846
Completed
Phase 3
Nilotinib in PH+, BCR-, ABL+ CML PatientsChronic Myeloid LeukemiaNCT01535391Gruppo Italiano Malattie EMatologiche dell'Adulto109
Completed
Phase 1
Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of DigoxinHealthyNCT00860223Puma Biotechnology, Inc.27
Completed
Phase 2
Nilotinib in Parkinson's DiseaseParkinson DiseaseNCT03205488Northwestern University76
Completed
Phase 1
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer PatientsNeoplasms, BreastNCT00258050GlaxoSmithKline24